Cancer Patients' protein needs under the microscope
NCT ID NCT04144907
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to figure out the right amount of protein for people with colorectal or breast cancer. Muscle loss is common in cancer patients and can lead to worse outcomes, but current protein guidelines aren't based on solid evidence. Researchers will use a simple, non-invasive test to measure protein needs in 40 patients, with the goal of improving future nutrition recommendations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2021
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Outpatients age 45-80 years; * Patients attending the new patient clinic at the Cross Cancer Institute with a diagnosis of colorectal cancer or breast cancer (stages II to III); * Able to complete baseline visits within approximately 4 weeks of starting chemotherapy OR after a minimum of 4 weeks post-surgery if not undergoing chemotherapy; * Ambulatory. Exclusion Criteria: * Premenopausal women due to impact on protein requirements; * Received anti-cancer hormone treatment or immunotherapy in the 4 weeks before first baseline visit; * Renal impairment based on a creatinine clearance for estimated glomerular filtration rate (eGFR) of \<60 mL/min * Abnormal glucose metabolism based on a fasting glucose level \>6mmol/L and an HbA1c \>5.7% or as reviewed by study team; * Comorbidities or medications that would interfere with the participants ability to follow the study protocol or the quality of the data(e.g. diabetes, class III obesity, hormone therapy, another active cancer diagnosis); * Unable/unwilling to provide urine, breath and blood samples (e.g. oxygen tank, catheter, etc.); * Unable to eat the meals provided (i.e. receiving parenteral or enteral nutrition, severe allergies); * Substance dependent (e.g. alcohol, cigarettes, illicit drugs) and unable to follow study protocols.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2R3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back